NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.